multiple sclerosis and glp 1 Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine From metabolism to mind: The
Description
[DOI] [PubMed] [Google Scholar] 18.Gupta V
The STEP-HFpEF DM trial investigated whether the changes in glucose levels in HFpEF patients with obesity moderates the treatment benefits of GLP-1 RAs
The companys lead asset is in Phase 3 with decent phase 2 data
Retatrutide at 12mg produces 24.2% average weight loss over 48 weeks
Gastrointestinal Effects : Common side effects include nausea, vomiting, diarrhea, and constipation
